Pharming Group N.V. (PHARM) Wins FDA Priority Review for Joenja sNDA in Younger Children

FDA accepted Pharming’s sNDA for lower Joenja doses in children 4+ weighing 13—27 kg with APDS and granted Priority Review. PDUFA target action date is Jan 30, 2027.Material DetailsContext by AI AnalystThis is a mid-cycle regulatory step advancing Joenja’s pediatric expansion beyond the recent U.S…